Longtime Genzyme Holdout Meeker Passes Reigns To Sibold
Executive Summary
Bill Sibold will take over the leadership of Sanofi's Cambridge-based Genzyme group as the unit begins the important launch of Dupixent. Meeker ends his career at Genzyme after 23 years.
You may also be interested in...
Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals
Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval
CEO Olivier Brandicourt says Sanofi's Le Train, France, fill-and-finish facility should be back in FDA’s good graces before the PDUFA goal date for another Sanofi antibody, dupilumab.